Highlights on endoglin (CD105): from basic findings towards clinical applications in human cancer
AUTOR(ES)
Fonsatti, Ester
FONTE
BioMed Central
RESUMO
Antibody targeting of tumor-associated vasculature is a promising therapeutic approach in human cancer; however, a specific cell membrane marker for endothelial cells of tumor vasculature has not been discovered yet. Endoglin (CD105) is a cell-surface glycoprotein most recently identified as an optimal indicator of proliferation of human endothelial cells. The finding that CD105 is over-expressed on vascular endothelium in angiogenetic tissues has prompted several pre-clinical studies designed to get a deeper understanding on the role of CD105 in angiogenesis, and to evaluate the most appropriate clinical setting(s) to utilize CD105 as a therapeutic target. In this review, the foreseeable clinical applications of CD105 in human cancer are discussed.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=441416Documentos Relacionados
- Expression of endoglin (CD105) in cervical cancer
- Expression of endoglin, CD105, in conjunctival melanocytic nevi: Is it suspicious like in thyroidology? Oculi plus vident quam oculus?
- Clinical Immunohematology: Basic Concepts and Clinical Applications
- Transesophageal echocardiography: basic principles and clinical applications
- Handbook of basic pharmacokinetic including clinical applications
